HER3 CHO Cell Line

Catalog #
82299
$9,250 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

HER3 CHO Cell Line is a CHO-K1 cell line expressing HER3 (human epidermal growth factor receptor 3) (NM_001982.2, also known as receptor tyrosine-protein kinase erbB-3) under the control of a cytomegalovirus (CMV) promoter. This cell line was generated by lipid-mediated transfection followed by hygromycin selection and limited dilution. Individual clones were screened for HER3 expression levels by flow cytometry, and a clone was selected to generate this cell line.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, Receptor tyrosine-protein kinase erbB-3, ERBB3
Product Info
Storage and Usage
Citations
Host Cell Line
CHO-K1 cells, Chinese Hamster Ovary, epithelial-like cells, adherent
Supplied As
Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Materials Required But Not Supplied
Name Ordering Information
Thaw Medium 3 BPS Bioscience #60186
Growth Medium 3B BPS Bioscience #79529
UniProt #
P21860
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

HER3 (human epidermal growth factor receptor 3) is a transmembrane protein encoded by the ERB3 gene. HER3 is broadly expressed in human tissues however, increased expression of HER3 has been linked to a variety of solid tumors including ovarian, breast, colon, and gastric cancers and correlates with decreased overall survival in colorectal cancer patients. HER3 has the unique property of being inherently catalytically inactive but still being able to participate in ligand binding, forming heterodimers with nearby receptors of the HER family. The formation of these dimers initiates a cascade of downstream signaling steps critical to cell proliferation. The binding and subsequent phosphorylation of HER3 by HER2 or EGFR (epidermal growth factor receptor) has been found to play a role in tumor growth and drug resistance. Due to its cell surface expression in a variety of cancers and correlation with decreased survival, HER3 is a prospective therapeutic target for antibody-drug conjugate (ADC) development.

References

Beji A., et al., 2012 Clin Cancer Res. 18(4):956-68
Criscitiello C., et al., 2021 J Hematol Oncol. 14(1):20
Jaiswal B, et al. 2013 Cancer Cell. 23(5):603-17
Littlefield P, et al., 2014 Sci Signal. 7(354):ra114
Zhou B, et al., 2006 Cancer Cell. 10(1):39-50